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Abstract 1 
Background. The vascular endothelial growth factor (VEGF) and transforming growth factor 2 
(TGF)-β pathways regulate key biological features of glioblastoma. Here we explored 3 
whether the TGF-β pathway which promotes angiogenesis, invasiveness and 4 
immunosuppression, acts as an escape pathway from VEGF inhibition. 5 
Methods. The role of the TGF-β pathway in escape from VEGF inhibition was assessed in 6 
vitro and in vivo and by gene expression profiling in syngeneic mouse glioma models. 7 
Results. We found that TGF-β is an up-stream regulator of VEGF whereas VEGF pathway 8 
activity does not alter TGF-β pathway in vitro. In vivo, single agent activity was observed for 9 
the VEGF antibody B20-4.1.1 in three, and for the TGF-β receptor I antagonist LY2157299 in 10 
two of four models. Reduction of tumor volume and blood vessel density, but not induction of 11 
hypoxia, correlated with benefit from B20-4.1.1. Reduction of pSMAD2 by LY2157299 was 12 
seen in all models, but did not predict survival. Resistance to B20 was associated with anti-13 
angiogenesis escape-pathway-gene-expression whereas resistance to LY2157299 was 14 
associated with different immune response gene signatures in SMA-497 and GL-261 on 15 
transcriptomic profiling. The combination of B20 with LY2157299 was ineffective in SMA-16 
497, but provided prolongation of survival in GL-261, associated with early suppression of 17 
pSMAD2 in tumor and host immune cells, prolonged suppression of angiogenesis, and 18 
delayed accumulation of tumor infiltrating microglia/macrophages.  19 
Conclusions. Our study highlights the biological heterogeneity of murine glioma models and 20 
illustrates that co-targeting of the VEGF and TGF-β pathways might lead to improved tumor 21 
control only in subsets of glioblastoma. 22 
 23 
  24 
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 2 
Introduction 3 
Glioblastoma remains a universally fatal neoplasm despite some advances in its 4 
multidisciplinary management, e.g., the introduction of combined modality treatment 5 
including post-surgical radiotherapy with concomitant and maintenance temozolomide 6 
(TMZ/RTTMZ) 1,2. Several current strategies of glioblastoma treatment focus on the 7 
inhibition of angiogenesis, largely the VEGF pathway . Yet, the lead compound bevacizumab 8 
has not been approved in Europe for treatment of recurrent glioblastoma because an effect on 9 
overall survival has not been demonstrated, and the recently completed EORTC 26101 trial 10 
failed to demonstrate superior survival with the combination of bevacizumab with lomustine 11 
over lomustine alone 3. Further, two phase III trials in the newly diagnosed setting achieved 12 
prolonged progression-free survival, but not overall survival 4,5. While the potential clinical 13 
benefit of improving progression-free survival is not disputed, these study results call for 14 
combination therapies of VEGF antagonism with other targeted agents that may extend 15 
progression-free survival further and allow to confer a survival benefit. 16 
One likely explanation for the failure of VEGF antagonism to prolong overall survival is the 17 
induction of a biological change in tumors that eventually fail bevacizumab and then seem to 18 
be rather refractory to all further treatments. While it has been claimed that VEGF antagonism 19 
induces a more infiltrative phenotype in animal models 6, this assumption has been confirmed 20 
neither in retrospective analyses of recurrent glioblastoma patients 7 nor in the AVAglio trial8. 21 
TGF-β is a multifunctional cytokine implicated in the pathogenesis of glioblastoma, based on 22 
immunosuppressive properties and promotion of migration, invasion, angiogenesis and stem 23 
cell maintenance 9. Therapeutic activity of TGF-β antagonism has been demonstrated in 24 
animal models of glioma, but translation of TGF-β antagonism into the clinic has remained 25 
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challenging. The most advanced TGF-β antagonist is the receptor kinase inhibitor, 1 
LY2157299 10,11, which is currently explored in newly diagnosed and recurrent glioblastoma . 2 
There are multiple potential interdependencies between angiogenesis and the TGF-β pathway. 3 
Importantly, TGF-β has been identified as a positive up-stream regulator of VEGF mRNA 4 
expression and release and angiogenesis in cancer and non-neoplastic cells 12-16, providing a 5 
strong rationale for combining TGF-β and VEGF inhibition. Accordingly, we here explored 6 
the crosstalk between these pathways in syngeneic murine glioma models and asked whether 7 
co-targeting the VEGF and TGF-β pathways provides a new perspective for the treatment of 8 
glioblastoma. 9 
 10 
Materials and methods 11 
Reagents 12 
Recombinant human TGF-β2 was purchased from R&D systems (Minneapolis, MN) and 13 
murine VEGF (VEGF120) from biolegend (San Diego, CA). B20-4.1.1 (B20) was kindly 14 
provided by T. R. Schwartz (Genentech, South San Francisco, CA), cediranib by AstraZeneca 15 
(London, UK) and LY2157299 (LY) by Eli Lilly & Co. (Indianapolis, MN). 16 
 17 
Cell lines 18 
Murine SMA-497, SMA-540 and SMA-560 glioma cells were kindly provided by D.D. 19 
Bigner (Durham, NC). GL-261 cells were received from the National Cancer Institute 20 
(Frederick, MD).  21 
 22 
  23 
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Viability and clonogenicity assays 1 
Viability was assessed after pooling adherent and floating cells by trypan blue dye exclusion. 2 
Clonogenicity was assessed as previously described 17. Cells were treated with either 3 
LY2157299 (Eli Lilly & Co. 1µM), cediranib (AstraZeneca, 100 nM) or B20 (Genentech, 100 4 
µg/ml)..  5 
 6 
Real-time PCR (RT-PCR) 7 
Total mRNA for gene expression analyses was extracted from murine glioma cells after 24 h 8 
incubation in serum-free medium (SFM) or from in vivo tumor tissue13. For RT-PCR, gene 9 
expression was measured using the Real Time PCR System 7300 (Applied Biosystems, Foster 10 
City, CA) with SYBR Green Master Mix (AppliChem, Darmstadt, Germany) and primers at 11 
optimized concentrations.  12 
 13 
Immunoblot analyses 14 
For immunoblot analysis, whole cell lysates were prepared, proteins were separated under 15 
denaturating conditions following blotting and antibody detection.  16 
 17 
Enzyme-linked immunosorbent assay (ELISA)  18 
Supernatants from subconfluent glioma cell cultures (treated or untreated) were analysed.  19 
 20 
Animal studies 21 
The care and treatment of all animals was in accordance with the Swiss Federal Law on the 22 
Protection of Animals, the Swiss Federal Ordinance on the Protection of Animals and the 23 
guidelines of the Swiss confederation (permission number 38/2012). For intracranial tumor 24 
cell implantation, 2 μl of a single cell suspension in PBS were injected (1 μl/min) into the 25 
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right striatum. 5,000 SMA or 20,000 GL-261 cells were implanted in VM/Dk or C57Bl/6 1 
mice, respectively (n=10 per group). 2 
 3 
Immunohistochemical analysis 4 
Cryosections were fixed, blocked and stained with primary, followed by secondary 5 
antibodies.  Subsequently, quantification of immunohistological stainings was performed.   6 
 7 
Immunofluorescence microscopy 8 
Immunofluorescence studies were carried out on cryosections of tumor-bearing mouse brains 9 
and data analysis was performed with Bitplane Imaris (Bitplane) software 18.  10 
 11 
Analysis of gene expression data 12 
The generation of the microarray analysed herein has been described 19.  13 
 14 
Statistical analyses 15 
All in vitro data are representative of experiments performed in three independent 16 
experiments with similar results. All statistical analyses were performed using Prism 5 17 
(GraphPad Software, La Jolla, CA). 18 
 19 
For additional methods, please see Supplementary Information.  20 
 21 
  22 
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Results 1 
Characterization of VEGF and TGF-β1/2 ligand/receptor expression in mouse 2 
glioma cells 3 
VEGF-A (VEGF) mRNA was constitutively expressed by all cell lines, with the highest levels 4 
in GL-261 and SMA-560. In contrast, the highest levels of protein release were observed in 5 
SMA-540 and SMA-560 (Fig. 1A). VEGF receptor (VEGFR)1 mRNA was expressed in all 6 
cell lines and protein levels correlated well, with highest levels in SMA-560. SMA-560 7 
showed the highest VEGFR2 mRNA levels followed by SMA-540, and protein was only 8 
detected in SMA-540 and SMA-560 (Fig. 1B). We also examined ex vivo tumoral mRNA 9 
expression of ligands and receptors, using syngeneic normal brain tissue (NBT) of VM/Dk 10 
and C57BL/6 mice as a reference. In vitro maintained monolayer cultures (MC) and mouse 11 
gliomas in vivo (T) showed similar VEGF mRNA levels (Fig. S1A). Compared with MC, 12 
there were higher VEGFR1 mRNA in SMA-497 and GL-261, and higher VEGFR2 mRNA 13 
levels in all models in vivo (Fig. S1B,C), suggesting a major contribution from tumor blood 14 
vessels or up-regulation of expression in tumor cells in vivo. Immunohistochemical stainings 15 
of VEGFR2 levels revealed a major contribution from tumor cells, even masking a typical 16 
vessel staining pattern, which, however, became readily visible in tumors stained for CD31 17 
(see below) (Fig. S1D,E). 18 
TGF-β1/2 mRNA was abundant in all four models. There was no apparent correlation between 19 
mRNA and protein levels, and TGF-β1 consistently exceeded TGF-β2 protein levels in the 20 
supernatant. TGF-β receptor 2 (TGFβR2) and activin receptor-like kinase 5 (ALK-5) were 21 
expressed in all models at variable levels, with correlation between mRNA and protein (Fig. 22 
1C,D). TGF-β1 but not TGF-β2 mRNA was enhanced in vivo in SMA-497, SMA-560 and GL-23 
261. While ALK-5 mRNA was consistently increased in vivo, there was a mixed pattern for 24 
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TGFβR2 mRNA expression with increased expression in SMA-560, and a trend for decreased 1 
expression in the other models (Fig. S1F-I).  2 
 3 
Modulation and consequences of VEGF and TGF-β1/2 signaling in vitro 4 
We observed an increase in pVEGFR1 levels in response to exogenous VEGF in SMA but not 5 
in GL-261 glioma cells. pVEGFR2 was increased upon VEGF stimulation in SMA-540 and 6 
SMA-560 (Fig. S2A). An increase in pSMAD2 was observed in all models after exposure to 7 
exogenous TGF-β2. LY2157299 attenuated constitutive and induced SMAD2 phosphorylation 8 
(Fig. S2B). Neither VEGF pathway inhibition using B20 nor relevant concentrations of 9 
cediranib nor TGFβ pathway inhibition by LY2157299 affected viability or clonogenicity 10 
(Fig. S2D,E). 11 
 12 
Murinized bevacizumab prolongs survival in SMA-540, SMA-560 and GL-261 13 
glioma models 14 
We next determined single agent activity of B20 treatment in the four mouse glioma models. 15 
Histological analyses of tumors harvested when the first clinical symptoms occurred (early-16 
stage) revealed reduced tumor volumes in all models except SMA-497. Tumor volume 17 
reduction was not paralleled by changes in Ki-67 labeling (Fig. 2A,B). Solvent-treated tumors 18 
possessed well-delineated margins whereas tumor borders in the B20 treatment groups were 19 
frayed and surrounded by numerous smaller satellites in all models (Fig. S3A,B). The number 20 
of intratumoral vessels was decreased in SMA-540, SMA-560 and GL-261, but not in SMA-21 
497 (Fig. 2C, Fig. S3C). Vessel morphology was specifically changed in GL-261 with 22 
decreased vessel diameter. CA IX staining as a surrogate marker for hypoxia was strongly 23 
induced in SMA-540 and SMA-560, but still not reaching constitutive levels of the SMA-497 24 
model (Fig. 2D, Fig. S3D). In general, CA IX staining was inversely related to CD31 labeling, 25 
confirming that hypoxia develops with increasing distance from blood vessels (Fig. S3F). 26 
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Finally, B20 prolonged survival in the SMA-540, SMA-560 and GL-261 models, but not in 1 
SMA-497 (Fig. 2F, Table S1). Our hypothesis of induced activation of the TGF-β pathway as 2 
an escape route from VEGF inhibition led us to predict increased pSMAD2 levels in B20-3 
treated tumors at least at progression. However, we observed decreased pSMAD2 levels in 2 4 
of 4 mouse models in vivo, and no change in the other two models, in fact, there was an 5 
association between decreased pSMAD2 levels and benefit from B20 (Fig. 2E, Fig. S3E). 6 
This decrease in pSMAD2 levels was observed in tumor cells and tumor-infiltrating 7 
leukocytes. Tumor cells were more frequently pSMAD2-positive than host cells indicating 8 
that tumor cells may be more responsive to TGF-β than host cells (Fig. S3G). Further, we 9 
noted that, in sharp contrast to the initial hypothesis of B20-triggered hypoxia followed by 10 
hypoxia-induced, TGF-β-mediated, invasiveness, induction of hypoxia and reduction of 11 
pSMAD2 were seen in the same models. Accordingly, all four cell lines responded to hypoxia 12 
with decreased pSMAD2 levels in vitro, too (Fig. S2C). Bioinformatic analyses of previously 13 
published data 19 focusing on angiogenesis gene sets (Table S2) revealed that SMA-497 14 
express high levels of genes involved in angiogenic escape pathways (Fig. 2G, Table S3). 15 
Unsupervised clustering of significantly regulated genes further revealed that genes up-16 
regulated in SMA-497 were mainly down-regulated in GL-261, and vice versa (Figure 2G, 17 
encircled clusters). Further assessment of these gene clusters by STRING analysis visualized 18 
the differential activation or down-regulation of genes of the angiogenic genesets in SMA-497 19 
and GL-261 (Fig. S3H,I). 20 
 21 
LY2157299 prolongs survival in SMA-560 and SMA-540 murine glioma models 22 
Next we determined single agent activity of LY2157299 in the four mouse glioma models. 23 
Histological analyses of tumors harvested when the first clinical symptoms occurred revealed 24 
a trend towards reduced tumor volumes only in SMA-560 (Fig. 3A, Fig. S4A). We then 25 
explored whether exposure to LY2157299 suppressed pSMAD2 as a surrogate marker of 26 
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TGF-β pathway activity. pSMAD2 levels were decreased by LY2157299 in all models (Fig. 1 
3B, Fig. S4B, left), confirmed by immunoblot in SMA-560 (Fig. S4B, right). Intratumoral 2 
vessel density was unaffected in either model but vessel morphology was changed in all 3 
models, except SMA-497, towards a vasculature with decreased vessel diameter and lumina 4 
upon LY2157299 treatment (Fig. 3C, Fig. S4C). LY2157299 prolonged survival in SMA-560 5 
and SMA-540, but not SMA-497 or GL-261 (Fig. 3D, Table S1). Accordingly, transcriptomic 6 
analysis of TGF-β receptor signaling pathway gene sets (Table S4) showed SMA-540 and 7 
SMA-560 to be the cell lines with the highest TGF-β pathway activity (Fig. 3E, Table S5). 8 
The survival differences in the SMA-540 control groups in the studies reported in Figures 2 9 
and 3 is explained by variations in the tumorigenicity in this model which is the least 10 
tumorigenic. Transcriptomic profiling also revealed that the most immunogenic tumors as 11 
defined by Gene Ontology, SMA-497 and GL-261, exhibited differential clusters of up- and 12 
down-regulated genes involved in immune response pathways. Genes up-regulated in SMA-13 
497 were mainly down-regulated in GL-261, and vice versa (Fig. 3F encircled, Table S6,7). 14 
STRING analysis of the differentially regulated gene clusters visualized the differential 15 
activation or down-regulation of genes of the immune response-related gene sets in SMA-497 16 
and GL-261 (Fig. S4D,E). 17 
 18 
Reciprocal modulation of the VEGF and TGF-β pathway in vitro 19 
We next assessed the expression of ligands and receptors of the VEGF and TGF-β pathways 20 
in the mouse glioma models after reciprocal stimulation. First we explored whether 21 
modulation of VEGF signaling in glioma cells affected the TGF-β pathway. Exposure to 22 
exogenous VEGF, B20 or cediranib had no effect on TGF-β1/2 mRNA and protein levels (Fig. 23 
S5A,B) or pSMAD2 levels (Fig. S5C). Conversely, VEGF mRNA expression and protein 24 
release were induced by TGF-β2 in a LY2157299-sensitive manner. VEGF mRNA expression 25 
was also increased in all cells in response to hypoxia whereas protein levels were increased in 26 
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SMA-497, SMA-540 and GL-261 and remained similar in SMA-560 (Fig. S5D,E). 1 
Furthermore, we observed an increase in total VEGFR1 mRNA expression in response to 2 
TGF-β2 in SMA-497 and SMA-560 glioma cells which was decreased upon co-treatment with 3 
LY2157299 only in SMA-560. However, protein levels were increased in all models and this 4 
effect was blocked by LY2157299 (Fig. S5F). VEGFR2 levels in response to TGF-β2 5 
stimulation, analyzed in SMA-540 and SMA-560 cells only, were increased upon stimulation 6 
in a LY2157299-sensitive manner (Fig. S5G). Although LY2157299 alone reduced 7 
constitutive pSMAD2 levels (Fig. S2B), it had no effect on constitutive VEGF ligand or 8 
receptor mRNA expression or protein release in either cell line. 9 
 10 
Co-targeting of the VEGF and TGF-β pathways in vivo 11 
SMA-497 and GL-261 were chosen to explore a potential synergy between VEGF and TGF-β 12 
pathway inhibition. SMA-497 was chosen because it was refractory to either treatment as 13 
single agent, facilitating the detection of any possible synergy. GL-261 was chosen because 14 
LY2157299 alone was not active whereas B20 was. A gain from co-treatment would indicate 15 
that the TGF-β pathway assumes a different role in the context of VEGF inhibition. There was 16 
no survival benefit from co-treatment in SMA-497 whereas combination treatment was 17 
superior to either treatment alone in GL-261 (Fig. 4A-E, Table S1). Early reductions of tumor 18 
volumes and blood vessel density were seen in GL-261, but not SMA-497, and only in the 19 
B20-containing regimens, with no modulation by LY2157299. The volume differences in 20 
early-stage GL-261 tumors were abolished in end-stage tumors. However, reduced blood 21 
vessel density was only maintained in the co-treatment group, but not in the B20-only end-22 
stage tumors (Fig. 4A,B). Decreased vessel diameter and increased vessel wall thickness were 23 
observed with all therapeutic regimens in GL-261 (Fig. S6B,F). ZO-1 was used as a marker 24 
for tight junction staining showing a more regular staining pattern indicative for a restoration 25 
of endothelial barrier integrity (Fig. S6I-L). Co-treatment with LY2157299 prevented B20-26 
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induced increased tumor invasiveness in early stages, but this effect was abolished in end-1 
stage tumors (Fig. S6A,E). In GL-261, but not SMA-497 gliomas, the reduction of pSMAD2 2 
levels by LY2157299 alone was enhanced by co-treatment with B20 in early-stage responsive 3 
and in end-stage resistant tumors. In contrast, pSMAD2 levels were increased in B20-treated 4 
end-stage tumors, consistent with the TGF-β pathway as an escape route from VEGF 5 
inhibition, and this was not seen with combined treatment (Fig. 4C, Fig. S6C,G). There was 6 
no significant CA IX induction in either model in early-stage tumors whereas treatment 7 
resistance in the GL-261 co-treatment group was accompanied by an increase in CA IX 8 
staining from 18% to 39% positive tumor areas (Fig. 4D, Fig. S6D,H). Assessment of the role 9 
of TGF-β1/2 within angiogenesis gene clusters up-regulated in SMA-497 and GL-261 by 10 
STRING analysis revealed that TGF-β1/2 interact with only a small subset of up-regulated 11 
genes in SMA-497. Conversely, both molecules are integrated in the main network of 12 
functional gene interactions in GL-261 (Fig. 4F), indicating a possible role of TGF-β in 13 
mediating resistance to B20 therapy. 14 
 15 
Differential host cell responses to VEGF/TGF-β co-targeting 16 
To generate a broad overview on host cell infiltration, we assessed frequencies of leukocytes 17 
(CD45+), T cells (CD4+ and CD8+) and macrophages/microglia (CD11b+)in mono- and co-18 
treated SMA-497 and GL-261 early- and end-stage tumors (Fig. 5A-D, Fig. S7A-H). In GL-19 
261, only in early- but not in end-stage tumors, increased infiltration of CD11b+ cells upon 20 
B20 alone and increased numbers of cytotoxic T (CD8+) cells upon co-treatment were 21 
observed (Fig. 5C,D, Fig. S7C,D). Resistance to co-treatment was accompanied by decreased 22 
infiltration of CD45+ and CD11b+ cells in GL-261 end-stage gliomas when compared to 23 
solvent or B20 mono-treatment (Fig. 5A,D, Fig. S7E,H). 24 
pSMAD2 was detected in tumor cells rather than host leukocytes in GL-261 end-stage 25 
tumors. Due to the higher proportion of pSMAD2-positive tumor cells versus infiltrating 26 
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leukocytes, tumor cells were more affected by decreased pSMAD2 levels, although levels in 1 
single leukocytes were altered similarly, with a decrease upon LY2157299 and combined 2 
treatment, and an increase by B20 alone (Fig. 6A-D).  3 
 4 
pSMAD2 levels in response to bevacizumab treatment in human glioblastoma 5 
We also analysed human glioblastoma patients who underwent further surgery upon failure of 6 
bevacizumab. As groups, neither refractory tumors of 9 non-bevacizumab-treated patients, nor 7 
those of 5 patients failing on a bevacizumab-containing regimen, exhibited an increase or 8 
decrease in pSMAD2 levels whereas vessel density was decreased in the latter group (Fig. 9 
S8A-F). 10 
 11 
Discussion 12 
Interactions between human tumors and their specific microenvironment determine growth 13 
characteristics and responses to radiotherapy or pharmacotherapy 20. This notion is 14 
particularly true for glioblastoma which typically contains major host cell infiltrates which 15 
probably support rather than limit tumor growth 21-23. 16 
Here we focused on two cytokine-dependent signaling pathways attributed a major role in the 17 
pathogenesis of glioblastoma, VEGF and TGF-β, using a panel of syngeneic mouse gliomas 18 
as model systems 19. Responsiveness to VEGF and TGF-β stimulation as assessed by VEGFR 19 
and SMAD2 phosphorylation as well as a positive regulation of VEGF by TGF-β, but not vice 20 
versa, was confirmed in vitro ((Fig. 1, Fig. S1,S2,S5). Inhibition of neither pathway has 21 
prominent effects on glioma cell viability or growth in vitro (Fig. S2) although growth 22 
suppressive properties have been reported for TGF-β1 in the SMA-560 model 24. 23 
There was differential responsiveness to B20-mediated VEGF inhibition alone. While high 24 
expression of VEGF and VEGFR is consistent with responsiveness of SMA-560, the 25 
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responsiveness of SMA-540 was less well explained, and the expression levels of VEGF in 1 
GL-261 did not translate into superior efficacy of B20. The responsiveness of GL-261 despite 2 
unaltered proliferation and hypoxia is consistent with direct induction of cell death by VEGF 3 
inhibition in some mouse glioma models 25,26. A high constitutive level of hypoxia and failure 4 
to reduce blood vessel density in response to B20, consistent with VEGF-independent 5 
angiogenesis, were prominent features of the refractory SMA-497 model. Of note, full 6 
suppression of angiogenesis was not achieved in any model (Fig. 2 and Fig. S3). Although all 7 
SMA lines were derived from one tumor, they exhibited major variation in response to 8 
different treatment settings that were tentatively linked to differential transcriptomics 9 
specifically among angiogenesis-related gene sets (Fig. 2, Tables S2,S3). 10 
The TGF-βR1 inhibitor LY2157299 was active pharmacodynamically as assessed by a 11 
decrease of pSMAD2 levels in vivo, although no full suppression was achieved, indicating 12 
either insufficient pharmacodynamic properties and target coverage, or ALK-5-independent 13 
pathways maintaining pSMAD2 phosphorylation, or both (Fig. 3 and Fig. S4). The two 14 
models responsive to LY2157299 in vivo, SMA-540 and SMA-560, exhibited increased 15 
expression levels of genes of the TGF-β receptor signaling pathway (Fig. 3). Similar to anti-16 
angiogenic therapy, also TGF-β antagonism has been linked to vascular normalization and 17 
improved drug delivery 27. Accordingly, we observed morphological changes related to 18 
vascular normalization in tumor vessels upon LY2157299 treatment in all models, consisting 19 
of  increased vessel wall thickness and decreased vessel diameter (Fig. 3C, Fig. S4C). It is 20 
tempting to link these uniform changes in blood vessel morphology, induced by LY2157299, 21 
to the effects of TGF-β on VEGF and VEGFR expression in vitro (Fig. S4,5). A 22 
transcriptional profiling study of human glioblastoma vessels indicated key roles in the 23 
process of pathological angiogenesis for VEGF-A and TGF-β2 28. The decrease in pSMAD2 24 
levels in response to hypoxia in vitro and to hypoxia in association with B20 treatment in vivo 25 
in two of three responsive models was surprising (Fig. 2, Fig. S2) since no evidence suggests 26 
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that the TGF-β pathway is negatively regulated by hypoxia. Interestingly, pSMAD2 levels 1 
positively correlated with tumor proliferation in human glioblastoma 9. Accordingly, we also 2 
found parallel changes in the levels of both markers (Fig. 2, Fig. S2). 3 
VEGFR inhibition in vitro did not decrease pSMAD2 levels in any cell line (Fig. S5). Yet, the 4 
synergistic suppression of pSMAD2 levels by B20 and LY2157299 co-treatment in early-5 
stage tumors and increased pSMAD2 levels in end-stage tumors with B20 treatment alone are 6 
consistent with the hypothesis that enhanced TGF-β activity might promote eventual escape 7 
from VEGF inhibition at least in the GL-261 model. Immunohistochemical analysis of 8 
orthotopic U87MG gliomas had indeed revealed increased TGF-β protein levels upon anti-9 
VEGF treatment, too 29. 10 
Increased levels of CD11b-positive macrophages/microglia have been linked to refractoriness 11 
to anti-VEGF treatment 30 and attributed a role in the VEGF-independent restoration of tumor 12 
vessels by vasculogenic, but not angiogenic processes 31. Supporting this concept, we 13 
observed that co-targeting VEGF and TGF-βR1 decreased the numbers of intratumoral 14 
CD11b+ cells and that tumors failed to re-vascularize compared to B20 alone in GL-261 end-15 
stage tumors (Fig. 5 and Fig. S6,7). Similarly, coinhibition of VEGF and the angiopoietin-2 16 
pathway provided improved tumor control and reduced numbers of F4/80-positive 17 
macrophages in the GL-261 model 25. Possibly, targeting TGF-β alters CD11b+ cell 18 
recruitment via interacting with the CXCR4-CXCL12 axis since VEGFR inhibitors can up-19 
regulate chemokine (C-X-C motif) receptor 4 (CXCR4) in glioblastoma cells by a TGF-β-20 
dependent mechanism 32 and since TGF-β up-regulates CXCR4 expression in monocytes, 21 
macrophages, T naïve cells and other immune cell populations 33,34. 22 
Altogether, according to our analysis in the GL-261 model, the tumor-promoting role of TGF-23 
β would relate more to facilitating angiogenesis or vasculogenesis than to promote a more 24 
invasive phenotype even when combined with VEGF antagonists. This is because B20-treated 25 
tumors were more invasive early on when pSMAD2 levels were still low and because co-26 
 
 
17 
 
treatment with LY2157299 still suppressed tumor vasculature in end-stage disease (Fig. 2,4). 1 
Yet, B20-induced hypoxia may ultimately promote lactate dehydrogenase activity 35 which in 2 
turn may stimulate TGF-β signaling associated with  an angiogenic signaling 36. 3 
Unexpectedly, we observed that mainly tumor cells but not leukocytes exhibited 4 
phosphorylated SMAD2 (Fig. 6 and Fig. S3). Previous studies have already indicated that 5 
pSMAD2 levels are high in glioblastoma cells, indicating that tumor cells do not have to 6 
escape TGF-β signaling at least at the level of SMAD2 phosphorylation 9,37. However, 7 
pSMAD2 levels in B20-treated GL-261 end-stage tumors increased proportionally in tumor 8 
cells and leukocytes (Figure 6). Since the activation of TGF-β signaling in tumors has been 9 
linked to immunosuppression 38, increased pSMAD2 levels indicate a TGF-β-induced 10 
immunosuppressive tumor micromilieu during anti-VEGF treatment which might be an 11 
important factor of therapy failure. Yet, preliminary studies in paired human glioblastoma 12 
samples provided no evidence for enhanced pSMAD2 levels at recurrence, either without or 13 
with previous bevacizumab therapy (Fig. S8). 14 
Limitations of the present study include the challenges in determining volumes of infiltrative 15 
rodent gliomas, the restriction to mouse models based on long-term cell lines, and the 16 
exploration of co-treatment rather than sequential treatments. Moreover, we did not 17 
distinguish B20 or LY2157299 effects on tumor versus host cells and effects of B20 on 18 
VEGFR1 versus VEGFR2 signaling in mouse glioma cells 39, and the human patient cohort 19 
was small. 20 
Our study highlights the relevance of hypoxia in the malignant phenotype of glioblastoma and 21 
its resistance to therapy. SMA-497 showed the highest constitutive level of hypoxia and was 22 
refractory to all therapeutic interventions. GL-261 eventually became hypoxic when escaping 23 
combination therapy (Fig. 4 and Fig. S6). We conclude that at least for subsets of 24 
glioblastomas, co-targeting of VEGF and TGF-β pathways might result in a permanent 25 
vascularization deficiency which results in prolonged tumor control. Ultimately, however, 26 
 
 
18 
 
such microenvironment-targeting therapies may only be successful if combined with 1 
pharmacological or cell-based therapies that exert relevant tumor cell cytotoxicity, since the 2 
major cell biological changes observed in selected models did not translate into major gains in 3 
survival 4 
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Figure legends 1 
Fig. 1 Expression of VEGF and TGF-β pathway ligands and receptors in mouse glioma 2 
models in vitro. SMA-497, SMA-540, SMA-560 and GL-261 cells were studied for  gene 3 
expression. A, VEGF expression determined by RT-PCR for mRNA (top) and by ELISA for 4 
protein in the supernatant (bottom) in vitro. B, VEGFR1,2 expression determined by RT-PCR 5 
(top) and immunoblot (bottom) in vitro. C, TGF-β1/2 expression determined by RT-PCR 6 
(top) and ELISA in the supernatant (bottom) in vitro. D, TGF-βR2 and ALK-5 expression 7 
determined by RT-PCR (top) and immunoblot (bottom) in vitro. Values of densitometric 8 
analysis relative to β-actin are shown below the immunoblot panels in B and D. 9 
Fig. 2 Differential effects of murinized bevacizumab on angiogenesis and growth of murine 10 
gliomas. Syngeneic mice intracranially implanted with SMA-497, SMA-540, SMA-560 or 11 
GL-261 cells were treated twice weekly with 5 mg/kg B20 or PBS from day 7 on. Brain 12 
sections (early-stage) were analysed. A, Tumor volumes. B, Ki-67 . C, CD31+ capillaries D, 13 
CA IX+ areas. E, pSMAD2. Data are expressed as mean and SEM (*p<0.05, **p<0.01, 14 
****p<0.0001, unpaired student t-test, B20 versus solvent). F, Kaplan-Meier survival curves 15 
of glioma-bearing mice (log-rank test, considered significant for p<0.05). G, Angiogenic gene 16 
expression heatmaps obtained by unsupervised comparison of genes differentially expressed 17 
in the four mouse glioma cell lines. The heatmaps indicate high to low expression levels as 18 
red to blue color coding. Up- or downregulated gene clusters in SMA-497 and GL-261 cells 19 
are encircled in red or blue. 20 
Fig. 3 Differential effects of LY2157299 on the growth of murine gliomas. Mice 21 
intracranially implanted with SMA-497, SMA-540, SMA-560 or GL-261 cells were treated 22 
daily with LY2157299 at 150 mg/kg or control solvent from day 7 on. Brain sections (early-23 
stage) were analysed. A, Tumor volumes. B, pSMAD2 and CD31+ capillaries (C). Data are 24 
 
 
25 
 
expressed as mean and SEM (*p<0.05, ****p<0.0001, unpaired student t-test, LY2157299 1 
versus solvent). D, Kaplan-Meier survival curves of glioma-bearing mice (log-rank test was 2 
considered significant for p<0.05). E,F, Gene expression heatmaps were obtained by 3 
unsupervised comparison of genes differentially expressed in the four mouse glioma cell lines 4 
for the TGF-β signaling (E) and immune response (F) pathways. The heatmaps indicate high 5 
to low expression levels as red to blue color coding. Up- or downregulated gene clusters in 6 
SMA-497 and GL-261 cells are encircled in red or blue. 7 
Fig. 4 Effect of combined B20 and LY2157299 treatment in SMA-497 and GL-261 syngeneic 8 
models in vivo. Syngeneic mice were intracranially implanted with SMA-497 or GL-261 cells 9 
and treated twice weekly with 5 mg/kg B20 or daily with 150 mg/kg LY2157299 or 10 
corresponding solvents or both from day 7 on. Brain sections from SMA-497 (early-stage) 11 
and GL-261 (early- and end-stage) were studied. Tumor volumes (A) and CD31+ capillaries 12 
(B). C, pSMAD2 . D, CA IX+ areas (*p<0.05, **p<0.01, ***p<0.001, one-way ANOVA 13 
followed by Tukey’s post hoc test confidence interval 95%, treated versus solvent, 14 
+++p<0.001, B20+LY2157299 versus B20, ##p<0.01, B20+LY2157299 versus LY2157299). 15 
E, Kaplan-Meier survival curves (Gehan-Breslow-Wilcoxon test, considered significant for 16 
p<0.05). F, Gene cluster analysis. Functional interactions between TGF-β1/2 and genes 17 
upregulated in angiogenic profiles in SMA-497 (left) and GL-261 (right) were analyzed in 18 
Affymetrix micro-array based gene expression profiling by STRING analysis. Interactions 19 
with high confidence score of 0.700 were integrated to the interactome. Clusters were 20 
determined by MCL algorithm and presented with different node colors. Inter-cluster edges 21 
are represented by dashed-lines. 22 
Fig. 5 Modulation of tumor immune cell infiltration in combined B20- and LY2157299-23 
treated syngeneic models in vivo. Brain sections from SMA-497 (early-stage) and GL-261 24 
(early- and end-stage) were examined. A, CD45+ leukocytes.  B, CD4+ T helper cells. C, 25 
 
 
26 
 
CD8+ cytotoxic T cells. D, CD11b+ monocytes/microglia. Data are expressed as mean and 1 
SEM (*p<0.05 and **p<0.01, ***p<0.001 one-way ANOVA followed by Tukey’s post hoc 2 
test confidence interval 95%, treatment versus solvent, #p<0.05, B20+LY2157299 versus 3 
LY2157299, +p<0.05 B20+LY2157299 versus B20).  4 
Fig. 6 Modulation of pSMAD2 levels and tumor immune cell infiltration in B20 and 5 
LY2157299 co-treated GL-261 syngeneic model in vivo. Brain sections (end-stage) were 6 
examined. Staining of tumor sections was assessed with DAPI (A, blue), pSMAD2 (B, green) 7 
and CD45 (C, red). Merged images are shown in (D). CD45+/pSMAD2+ leukocytes are 8 
marked by arrow heads. Size bars correspond to 50 µm.  9 
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Supplementary Table 1. Sensitivity of mouse glioma models to VEGF antibody B20 
or the TGF-βR1 (ALK-5) antagonist LY2157299 alone or their combination in vivo. 
 
 Cell line  
 SMA-497 SMA-540 SMA-560 GL-261 
 Median survival (range) [days]  
Treatment     
Control 14 (13–17) 31 (27–44) 14.5 (12–14) 20 (19-24) 
B20 15 (13–20) 48 (41–55) 32.5 (20->40*) 27.5 (24->40*) 
 ns p=0.0009 p=0.0007 p=0.0025 
Control 14 (12–18) 42 (27->60*) 13 (11–14) 17 (15 – 22) 
LY2157299 14 (12–19) >60 (44->60*) 17 (12 – 18) 17 (15–22) 
 ns ns p=0.014 ns 
Control 15 (14–16)   19.5 (17–44) 
B20 15 (14–17)   28 (22–41) 
LY2157299 15.5 (14–17)   19 (17–32) 
B20+LY2157299 16 (15–17)   33 (25–41) 
 ns   p=0.0166  
(cotreatment vs B20) 
p<0.0001 
(cotreatment vs LY) 
* censored because experiment was terminated at day 40 or day 60 
 
Supplementary Table 2. Gene sets of angiogenic profiles as defined by Gene 
Ontology classification schemes. 
Angiogenesis related genes (all genes analysed) 
Ctsh  
Cdc42 
Pdcl3 
Col3a1 
Cxcr2 
Chil1 
Tnfsf4 
Cd34  
Tgfb2  
Vash2  
Mfsd7b  
Cited2 
Lama4  
Nodal 
Itgb2 
Tbxa2r 
Btg1  
E2f7 
Sash1  
Hey2  
Nr2e1 
Ccm2 
Flt4 
Pik3r6 
Ccl11 
Col1a1  
Dlx3 
Ramp2  
Map3k3 
Sphk1  
Uts2r 
Prop1 
Alox12  
Brca1  
Prkca 
Jmjd6 
Hif1a 
Psen1 
Rhob 
Prkd1 
Pgf 
Agtr1a 
Foxc1 
Erap1 
Mef2c  
Esm1 
Prl2c2  
Pdcd6 
Aggf1 
Isl1 
Wnt5a  
Gdf2 
Loxl2 
Bmp4  
Cma1 
Gata4  
Ptk2b  
Cysltr2 
C6 
Mtdh 
Adm2  
Acvrl1 
Otulin  
Angpt1  
Ptk2 
Pdgfb 
Rapgef3 
Crkl 
Tbx1 
Pkd1 
Vegfa 
Lrg1 
C3  
Cyp1b1  
Mib1 
Gata6  
Fgf1 
Lox  
Ccbe1 
Tcf7l2 
Nrarp 
Egfl7 
Col5a1 
Rapgef1 
Eng 
Itgav  
Pax6  
Thbs1 
Angpt4 
Plcg1 
Notch1  
Hc  
Grem1 
Il1a 
Il1b 
Foxs1 
Ptgis 
Sox18 
Fgf2  
Foxo1 
Sfrp2  
Gja5 
F3  
Lef1  
Ddah1  
Hey1  
Agtr1b 
Rapgef2 
Ntrk1  
Ecm1 
Chd7  
Tek 
Angptl3 
Ppap2b 
Epha2 
Uts2 
Shb 
Tie1 
Gja4 
Sema3e  
Hgf 
Nos3 
Add1 
Anxa3 
Tbx3  
Kdr 
Tgfbr3 
Ccl24 
Serpine1 
Cdx2 
Flt1 
Col1a2 
Aqp1 
Gata2 
Tnfrsf1a 
Hipk2 
Epha1 
C3ar1  
Prkd2 
Psg22 
Rras 
Fzd4 
Adm 
Parva 
Prkcb 
Dhcr7 
Sphk2  
E2f8 
Gpr124 
Vegfc  
Hmox1 
Cx3cl1  
Cdh13 
Foxf1  
Foxc2 
Nrp1  
Angpt2 
Gatad2a 
Agt 
Ets1 
Stra6 
Aldh1a2 
Ccr3 
Camp 
Tgfbr2 
Cx3cr1 
Cdx4 
Atp7a  
Cxcr3 
Cysltr1 
Chm 
Esx1 
 
 
Supplementary Table 3. Differentially regulated genes of angiogenic profiles of 
SMA-497 and GL-261 mouse glioma cell lines, as defined by Gene Ontology 
classification schemes. 
Angiogenesis-related 
genes up-regulated in 
SMA-497 
Angiogenesis-related 
genes up-regulated in 
GL-261 
Angiogenesis related 
genes down-regulated 
in GL-261 
 C3; Col1a1; Wnt5a; 
Lef1; Tbx3; Btg1; Vash2; 
Gata4; Tgfb2; Ddah1 
Hey1; Thbs1; Gata6 
Prl2c2; Lox; Sphk1 
CD34; Cyp1b1; Ntrk1 
Sfrp2; Angpt1; Vegfc; 
Cx3cl1; Bmp4; C3ar1 
Chd7; Serpine1; 
Sema3e; Notch1; Hc; 
Itgav; Brca1; Foxf1; 
Ramp2; Hey2; Alox12; 
Ptk2b; Adm2; Nrp1; 
Mfsd7b; Sphk2; Otulin; 
Ctsh; F3; Lama4; Mef2c; 
Pax6; Sash1; Fgf2; Atp7a 
Col1a1; Wnt5a; Lef1; 
Tbx3; Btg1; Vash2 
Gata4; Thbs1; Gata6 
Prl2c2; Lox; Sphk1 
C3; Ecm1; Rapgef3 
Gata2; Isl1; Aqp1;Eng 
Anxa3; Tgfbr3; Epha2 
Col1a2; Grem1;Cdh13 
Gpr124; CD34; Cyp1b1; 
Ntrk1; Sfrp2; Angpt1; 
Vegfc; Cx3cl1; Bmp4; 
C3ar1 
 
Supplementary Table 4. Gene sets of TGF-β receptor signaling pathways as 
defined by Gene Ontology classification schemes.  
TGF-β receptor signaling pathway related genes (all genes analysed) 
Col3a1 
Mstn 
Parp1 
Tgfb2 
Cited2 
Ptprk 
Nodal 
Usp15 
Trp53 
Arrb2 
Ccl2 
Nlk 
Wfikkn2 
Wfikkn2 
Smurf2 
Smurf2 
Fut8 
Fos 
Tgfb3 
Dusp22 
Gcnt2 
Smad5 
Map3k1 
Dcp1a 
Fermt2 
Gdnf 
Tab1 
Acvrl1 
Amhr2 
Ptk2 
Foxh1 
Pdgfb 
Itgb5 
Ltbp1 
Bambi 
Smad7 
Smad2 
Smad4 
Ltbp3 
Eng 
Bmp2 
Src 
Acvr1 
Fshb 
Dusp15 
Skil 
Smad9 
Bmpr1b 
Map3k7 
Tgfbr1 
Bmp8b 
Jun 
Bmp8a 
Pxn 
Tgfbr3 
Pdgfa 
Smurf1 
Col1a2 
Zyx 
Hipk2 
Tgfb1 
Arap1 
Ltbp4 
Hpgd 
Adam9 
Smad1 
Pml 
Smad3 
Smad6 
Tgfbr2 
Usp9x 
Cited1 
 
Supplementary Table 5. Differentially regulated genes of TGF-β signaling pathways 
of SMA-540 and SMA-560 mouse glioma cell lines, as defined by Gene Ontology 
classification schemes. 
TGF-β-related genes up-
regulated in SMA-540 
TGF-β-related genes up-
regulated in SMA-560 
Tgfbr3; Tgfb1; Smurf1; 
Itgb5; Eng; Col1a2; Bambi; 
Bmp2; Col3a1; Skil; Ltbp4; 
Zyx: Smurf2 
Dusp22; Map3k1 
Fut8; Tgfbr3; Tgfb1 
Smurf1; Itgb5; Eng 
 
Supplementary Table 6. Gene sets of immunogenic profiles as defined by Gene 
Ontology classification schemes. 
Immune response related genes (all genes analysed) 
Ilf2 
Oprk1 
Zap70 
Cd28 
Ctla4 
Ccl20 
Fcamr 
Il10 
Sbspon 
Prg4 
Fasl 
Xcl1 
Fcgr2b 
Cd24a 
Zfr2 
9230019H11Rik 
Enpp1 
Enpp3 
Susd2 
Osm 
Lif 
Il5 
Vtn 
Ccl7 
Ccl11 
Ccl12 
Ccl8 
Ccl4 
Csf3 
Tgtp1 
Ccl1 
Ccl5 
Ccl9 
Ccl6 
Ccr7 
Ccr10 
Map3k14 
Bmp6 
Hfe 
Cxcl14 
Il9 
Bmpr1a 
Tnfsf11 
C6 
C7 
Ptger4 
Enpp2 
Endou 
Cblb 
Vpreb1 
Nrros 
Ccr6 
H2-Oa 
H2-DMb2 
H2-Ob 
H2-Ab1 
H2-Eb1 
H2-Eb2 
Ltb 
H2-D1 
H2-M11 
H2-M10.5 
H2-M10.6 
Tnfsf9 
Vav1 
H2-K1 
Lst1 
H2-T24 
H2-T23 
H2-T22 
Gm7030 
H2-Bl 
H2-T10 
H2-T3 
H2-M10.2 
H2-M10.1 
H2-M10.3 
H2-M10.4 
H2-M9 
H2-M1 
H2-M5 
H2-M2 
Cd70 
Tnfsf14 
Colec12 
Fth1 
Cd274 
Nkx2-3 
Ms4a2 
Lax1 
Thbs1  
Procr 
Bpi 
Il1a 
Il1b 
Tnfsf10 
Il12a 
Cd1d2 
Il7 
Il2 
Il21 
Cd1d1 
Ifi44l 
Ccl27b 
Gm13304 
Tnfsf15 
Tnfsf8 
C8a 
Tinagl1 
Tnfrsf1b 
Cxcl5 
Cxcl3 
Cxcl15 
Cxcl1 
Cxcl2 
Cxcl13 
Oasl2 
Oas1b 
Oas1f 
Oas1h 
Oas3 
Oas1e 
Oas1c 
Oas1g 
Ccl26 
Ccl24 
Cxcl12 
Clec4e 
Cd4 
Mill1 
Mill2 
Igf1r 
Mylpf 
Psg17 
Cebpg 
Fcgrt 
Lat 
Ccl25 
Tnfsf13b 
March1 
Ccl22 
Cx3cl1 
Ccl17 
Irf8 
Il15 
Il18 
Tlr9 
Ccr8 
Ccr9 
Ccr2 
Myd88 
Ccr1 
Ccr1l1 
Ccr5 
Ccl28 
Eda 
Was 
Il13 
Csf2 
Il3 
Tnfsf12Tnfsf13 
Tnfaip1 
H2-Q1 
H2-Q2 
H2-Q4 
H2-Q6 
H2-Q10 
Il1f8 
Il1f6 
Prg2 
Prg3 
Traf6 
Oas1d 
Azgp1 
Cxcl9 
Gbp6 
Tgfbr3 
Cxcr5 
Smad3 
Smad6 
Tinag 
Ccr4 
 
Supplementary Table 7. Differentially regulated genes of immunogenic profiles of 
SMA-497 and GL-261 mouse glioma cell lines, as defined by Gene Ontology 
classification schemes. 
Immune response-
related genes up-
regulated in SMA-497 
Immune response-
related genes up-
regulated in GL-261 
Immune response-
related genes down-
regulated in GL-261 
Smad6; Map3k14 
Ccl9; Bmpr1a; Igf1r; 
Bmp6; Ccl8; Cd24a; Il15; 
Enpp2; Cx3cl1; Fcgrt; 
Ccl17; Cxcl1; Il7; Cxcl12 
Cxcl5; Cd1d1; thbs1 
Oasl2; Oas1g; Tgtp1 
Gbp6; Oas1b; Enpp1 
Ccl5; Cd274; H2−Bl 
Lst1; Mill2; Nrros 
Tnfsf10; Bpi; Psg17 
C7; H2−DMb2; Enpp3 
Ccl25; Tnfsf9; H2−Q4 
H2−K1; Oas3; H2−T23 
Azgp1; Tinagl1; Il18 
Smad3; Tnfrsf1b; Eda 
Lif; Cblb; Tgfbr3 
Colec12; ccl7 ; Cx3cl1; 
Fcgrt; Ccl17 ; Cxcl1; Il7; 
Cxcl12 ; Cxcl5; cd1d1 
 
Supplementary materials and methods 
Cell lines 
The cells have been characterized extensively in our laboratory 1 and are commonly cultured 
as adherent monolayers in Dulbecco`s modified Eagle medium (DMEM) (Gibco, Invitrogen 
AG, Basel, Switzerland) supplemented with 10% heat-inactivated fetal calf serum (FCS) 
(Biochrom KG, Zug, Switzerland) and 2 mM glutamine (Biochrom KG) (DM medium). 
Hypoxia treatment was done in a hypoxia chamber at 1% O2 atmosphere. 
 
Viability and clonogenicity assays 
Clonogenicity was assessed as previously described  2. Briefly, 100 cells per well were seeded 
in 96-well plates, allowed to adhere overnight, and treated for 24 h with either LY2157299 
(Eli Lilly & Co, 1 µM), cediranib (AstraZeneca, 100 nM) or B20 (Genentech, 100 µg/ml) in 
fresh medium followed by an observation period for 10 to 14 days in serum-containing 
medium. Cell density was assessed by counting crystal violet stained colonies.  
 
Real-time PCR (RT-PCR) and primers 
The conditions for RT-PCR were 40 cycles, 95°C/15s, 60°C/30s, 72°C/30s. Relative 
quantification of gene expression was obtained by comparison of cycle threshold values. 
Hypoxanthine phosphoribosyltransferase 1 (HPRT1) was used as a housekeeping gene and 
specific target gene expression was normalized to HPRT1 and calculated with the ΔCT-
method for relative quantification with respect to primer efficiency calculated by the standard 
curve method. The following mouse-specific primers were used: HPRT1 (forward 5'-
TTGCTGACCTGCTGGATTAC-3', reverse 5'-TTTATGTCCCCCGTTGACTG-3'), VEGF 
(forward 5'-CACGACAGAAGGAGAGCAGA-3', reverse 5'-
GGGCTTCATCGTTACAGCAG-3’), VEGFR1 (forward 5'-
AGAGGAGGATGAGGGTGTCT-3’, reverse 5’-GGGAACTTCATCTGGGTCCA-
3’),VEGFR2 (forward 5’-GCTCCTGACTACACTACCCC-3’, reverse 5’- 
AGGAAACAGGTGAGGTAGGC-3’), TGF-β1 (forward 5′-
TGGAGCAACATGTGGAACTC-3′, reverse 5′- GTCAGCAGCCGGTTACCA-3′), TGF-β2, 
(forward 5′-GCCCACTTTCTACAGACCCT -3′, reverse 5′- 
CCTTGCTATCGATGTAGCGC-3′), ALK-5 (forward 5’- TGGGACTTGCTGTGAGACAT-
3’, reverse 5’- CCACCAATAGAACAGCGTCG-3’) and TGF-βR2 (forward 5’-
CTGTTGCCTGTGTGACTTCG-3’, reverse 5’-AACGACTCCACGTTTTC-3’) (all 
Microsynth, Balgach, Switzerland). 
 
Immunoblot analyses 
For immunoblot analysis, whole cell lysates were prepared using RIPA lysis buffer containing 
1% NP-40, 0.5% sodium deoxycholate, 50 mM Tris/HCl pH 8.0, 150 mM NaCl, 5 mM 
EDTA pH 8.0, 0.1% SDS in Milli-Q water supplemented with 2 µg/mL aprotinin, 10 µg/mL 
leupeptin, 100 µg/mL phenylmethylsulfonyl fluoride, phosphatase inhibitor cocktails 2 and 3 
(Sigma Aldrich, St. Louis, MO). Protein levels were determined using BCA Protein Assay Kit 
(Pierce/Thermo Fisher, Madison, WI). After SDS-PAGE (8 – 12 % acrylamide gels) under 
reducing conditions with loading of equal amounts of proteins, proteins were transferred to 
nitrocellulose membranes (Biorad, Hercules, CA), blocked in Tris-buffered saline containing 
5% skim milk and 0.1% Tween 20 and incubated with the following antibodies at 
concentrations recommended by the manufacturers: anti-VEGFR1 (R&D Systems, AF471), 
anti-VEGFR2 (Cell Signaling, Leiden, Netherlands, #2479), anti-pSMAD2 (Cell Signaling, 
#3108), anti-ALK-5 (Santa Cruz Biotechnology, Inc., Dallas, TX, sc-9048), anti-TGFβR2 
(R&D Systems, AF532), anti-β-actin (Santa Cruz Biotechnology, Inc., sc-1616). 
Visualization of protein bands was accomplished using horseradish peroxidase (HRP)-
coupled secondary antibodies (Santa Cruz) and enhanced chemoluminescence (Pierce/Thermo 
Fisher, Madison, WI). For quantitative correlation analyses of baseline expression of total and 
phosphorylated proteins, band intensity was analyzed via densitometry using ImageJ software 
(http://imagej.nih.gov/ij/index.html, Open Source). 
 
Enzyme-linked immunosorbent assay (ELISA)  
Supernatants were collected from subconfluent glioma cell cultures after the indicated time 
periods. Treatments were performed in SFM for the indicated time periods. Cellular debris 
was removed by centrifugation and supernatants were concentrated using 3K-Amicon® Ultra-
4 Centrifugal Filter Units (Millipore AG, Zug, Switzerland). ELISA kits for murine VEGF 
(VEGF, eBiosciences, San Diego, BM5619/2), murine TGF-β1 (eBiosciences, BMS608/4) 
and TGF-β2 (R&D, MB200) were used. Results were normalized to the cell numbers at the 
time of harvesting. 
 
Animal studies 
Following anesthesia, a burr hole was drilled in the skull 2 mm lateral to the bregma. The 
needle of a Hamilton syringe (Hamilton, Darmstadt, Germany) was introduced to a depth of 3 
mm. A volume of 2 μl of a single cell suspension in PBS was slowly injected into the right 
striatum. In VM/Dk mice 5 x 103 SMA glioma cells were implanted, whereas in C57Bl/6 
mice 2 x 104 GL-261 cells were implanted (n=10 per group). Systemic treatment was 
performed by i.p. injections of B20 (5 mg/kg body weight twice weekly) or the solvent PBS, 
or by oral gavage delivering the TGF-βR1 inhibitor LY2157299 (150 mg/kg weight/daily) or 
the solvent (1% w/v HEC/0.25% v/v Tween 80/ 0.05 v/v Antifoam 1510-US in H2O). The 
mice were observed daily and euthanized when developing neurological symptoms or at 
defined time points for histological analysis as indicated. Three mice per group were 
commonly euthanized using a pre-randomization list when any mouse in the experiment 
became symptomatic (early-stage) in order to perform histological studies to assess tumor 
growth at an early stage. The remaining 7 mice were euthanized when displaying neurological 
symptoms to obtain survival or histological data (end-stage). Where indicated, mice brains 
were explanted for snap-frozen samples. All brains were collected upon euthanization, 
embedded in cryomoulds in Shandon Cytochrome yellow (Thermo Scientific, Waltham, MA) 
and frozen in liquid nitrogen. Tumor incidences and sizes were determined using hematoxylin 
and eosin stainings of 8 µm thick cryosections cut using a Microm HM560 (Microchom 
HM560, Thermo Scientific). Each experiment was performed at least twice. 
 
Immunohistochemical analysis 
Cryosections were fixed in 4% formalin, acetone or methanol/acetone for 10 min, air-dried, 
pretreated with 0.3-3% H2O2 and blocked in 10% rabbit or donkey serum or blocking solution 
(Candor Biosciences, Wangen, Germany). After blocking, the primary antibodies were 
applied for 1 h at 37°C or overnight at 4°C. Primary antibodies were polyclonal goat anti-CA 
IX (R&D Systems, AF2344, 1:50), monoclonal rat anti-CD4 (BD Pharmingen, 553727, 
1:100), monoclonal rat anti-CD8a (BD Pharmingen, BD550281, 1:50), polyclonal rabbit anti-
CD11b (Abcam, Cambridge, UK, ab75476, 1:400), monoclonal rat anti-CD31 (BD 
Pharmingen, Allschwil, Switzerland, BD550274, 1:50), monoclonal rat anti-CD45 
(Biolegend, San Diego, CA, 103102, 1:1000), monoclonal rabbit anti-Ki-67 (Epitomics, 
Burlingame, CA) and monoclonal rabbit anti-pSMAD2 (Cell Signaling, 3108, 1:1000). 
Biotinylated secondary antibodies, streptavidin and 3,3′-diaminobenzidine (DAB) were 
obtained from Dako (Baar, Switzerland). Histofine Simple Stain Mouse MAX PO secondary-
labelled antibody system was obtained from Nichirei (Tokyo, Japan). Secondary antibodies 
were incubated for 30 min at room temperature. The antigen antibody conjugates were then 
detected by staining with DAB (Dako) for 1-3 min. The nuclei were stained using 
hematoxylin for up to 4 min, washed in water and dehydrated twice in 96% ethanol, then 
twice in 100% ethanol and three times in xylol before mounting onto coverslips using Eukitt 
mounting medium (Sigma Aldrich). Quantification of immunohistological stainings was 
obtained from 4 regions of interest (ROI) from 3 tumors per group. Within tumor tissue, 
percentages of CD11b- and CD45-positive cells of all nucleated cells were determined, 
microvessel density (MVD) was calculated by counting CD31+ capillaries, and infiltrating 
CD4 and CD8a positive cells per ROI were counted. Quantification of pSMAD2-positive 
cells was performed by H scoring in four randomly selected, different microscopic fields of 
independent hotspots (tumor margin) and tumor centers on the basis of both the percentage of 
positive tumor nuclei and staining intensity in tumors 3. In brief, to obtain scores, staining 
intensity is scored as absent (0), mild (1), moderate (2) or strong (3) expression. The staining 
intensity value is multiplied by the percentage of cells showing each grade of positivity, thus, 
the maximum H score is 300 4,5. The surface detection function within the Image J software 
was used for the quantification of CD11b-, CD45- and Ki-67-positive cells and for Carbonic 
anidrase IX (CA IX)-positive areas. Tumor volumes were calculated using an approximation 
based on ellipsoid geometric primitive 6. 
 
Immunofluorescence microscopy 
Immunofluorescence studies were carried out on cryosections of tumor-bearing mouse brains 
and on paraffin-embedded sections from 14 paired surgical glioma samples from patients that 
were exposed to salvage therapy regimens without or with bevacizumab in between two 
surgical interventions. Briefly, formalin-fixed paraffin-embedded (FFPE) tumor tissue 
samples were deparaffinized with xylene for 30 min and rehydrated. The following antibodies 
were applied overnight at 4°C: polyclonal anti-CA IX (R&D Systems), monoclonal anti-
CD31 (BD Pharmingen), monoclonal pSMAD2 (Cell Signaling), monoclonal rat anti-
VEGFR1 (Biolegend, 136402, 1:50) and monoclonal rabbit anti-VEGFR2 (Cell Signaling, 
2479, 1:200). Binding specificity was controlled by IgG isotype control (Jackson 
Immunoresearch, West Grove, PA). For visualization, Alexa Fluor 488 goat anti-rabbit IgG 
(Life Technologies, Zug, Switzerland, A-11008) or Alexa Fluor 594 donkey anti-rat IgG (Life 
Technologies, A-21209) were applied. All sections were mounted in Dako Fluorescent 
Mounting Medium (Dako). DNA was stained with 4’,6-diamidino-2-phenylindole  (DAPI). 
Pictures were taken with a ×63 oil immersion objective (1.4 numerical aperture; Leica 
Microsystems, Heerbrugg, Switzerland). A CLSM Leica SP5 microscope (Leica 
Microsystems) attached to a diode and an argon laser was used to provide excitation at 405 
nm, 488 nm and 561 nm wavelengths. The emitted fluorescence light was detected via three 
adjustable photomultiplier detectors. Per brain section, two single images from randomly 
selected ROI were recorded and included in the quantification. The surface detection function 
within the Bitplane Imaris (Bitplane) software 7 was used for quantification of pSMAD2 
staining. 
 
Analysis of gene expression data 
The microarray data have been presented previously 1. Raw microarray data were calibrated 
and summarized using the hook method including quantile-normalization 8-10. The expression 
value of each gene was transformed into log10-scale and centered with respect to its mean 
value averaged over all samples investigated 11. Differential expression analysis was 
performed using pairwise comparisons of sample classes and by applying a shrinkage t-score 
combined with false discovery rate multiple test correction for judgement of significance 12. 
For functional analysis we applied gene set enrichment analysis based on predefined gene sets 
taken from the literature, from gene ontology classification schemes, or from gene lists 
determined in this study. All methods were implemented in the program opoSOM that was 
used for all analyses 13. 
 
  
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) analysis 
Functional gene interactions were analysed with the STRING Version 10 at http://string-
db.org 14. High confidence settings were applied, integrating combined scores higher than 
0.700. Cluster analysis was performed by application of the Markov Cluster algorithm 
(MCL).  
 
Statistical analyses 
All in vitro data are representative of experiments performed in three independent 
experiments with similar results. Statistical significance was assessed using either two-sided 
paired or unpaired Student’s t-test or one-way ANOVA with Tukey’s post hoc test for 
multiple analysis. Quantitative data are represented as mean ± standard deviation (SD) for in 
vitro or standard error of the mean (SEM) for in vivo experiments. A p value below 0.01 was 
considered significant. Kaplan Meier survival curves generated from the animal studies were 
analyzed using the log-rank test or the Gehan-Breslow-Wilcoxon test. A p value below 0.05 
was considered significant. All statistical analyses were performed using Prism 5 (GraphPad 
Software, La Jolla, CA). 
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Supplementary Fig. S1 VEGF and TGF-β pathway ligand and receptor expression in 
experimental mouse gliomas in vivo. A-C Explanted SMA-497, SMA-540, SMA-560 or GL-
261 mouse tumors (T) were studied for VEGF and VEGFR1,2 mRNA expression. MC and 
normal brain tissue of the respective mouse strain (VM/Dk or C57BL/6) served as references. 
(A) VEGF, (B) VEGFR1, (C) VEGFR2. Three ex vivo tissue samples per group were 
analysed. Data are expressed as mean and SD (*p<0.05, **p<0.01, unpaired student t-test, T 
versus MC). D,E, Immunofluorescent stainings of VEGFR2 in mouse glioma tissues (D) and 
normal brain tissue (E) were performed (size bar: 20 µM). F-I Explanted tumors (T) were 
studied for TGF-β1/2, TGF-βR2 and ALK-5 mRNA expression. MC and normal brain tissue 
of the respective mouse strain (VM/Dk or C57BL/6) served as references. (F) TGF-β1, (G) 
TGF-β2, (H) TGF-βR2, (I) ALK-5. Three ex vivo tissue samples per group were analysed 
(*p<0.05, **p<0.01, ***p<0.001, unpaired student t-test, T versus MC). Each experimental 
and control group contained 3 mice for histological examination and 3 animals for expression 
analysis. Each experiment was performed at least twice 
 
Supplementary Fig. S2 VEGF and TGF-β signaling in mouse glioma cells in vitro. A, 
pVEGFR1,2 levels after VEGF stimulation (400 ng/ml,5 min) were assessed by immunoblot. 
B, pSMAD2 levels of cells either treated with 1 µM LY2157299 or 2 ng/ml TGF-β2 or both 
(SMA-540, SMA-560 for 3 h, SMA-497, GL-261 for 24 h) were analyzed. C, pSMAD2 
levels were assessed under normoxic or hypoxic conditions (24 h, 1% O2). Values of 
densitometric analysis of pVEGFR and pSMAD2 protein levels, relative to β-actin, are shown 
below the immunoblot panels. D,E, Mouse glioma cells were exposed to LY2157299 (24 h, 1 
µM), cediranib (24 h, 100 nM) or B20 (24 h, 100 µg/ml). D, Viability was assessed by trypan 
blue exclusion assay. E, Clonogenic survival was assessed by measuring cell density via 
crystal violet staining. Quantitative data are expressed as mean and SEM (***p<0.001, one-
way ANOVA followed by Tukey’s post hoc test, confidence interval 99%, LY2157299 or 
cediranib versus DMSO) 
 
Supplementary Fig. S3 Differential effects of murinized bevacizumab on angiogenesis, 
leukocyte infiltration and growth of murine gliomas. Syngeneic mice intracranially implanted 
with SMA-497, SMA-540, SMA-560 or GL-261 cells were treated twice weekly with 5 
mg/kg B20 or PBS from day 7 on. a-e Brain sections from animals sacrificed when the first 
mice became symptomatic were stained with H&E (A) or by immunohistochemistry for Ki-67 
(B), CD31 (C), CA IX (D) or pSMAD2 (E). F, Vessel density and tumor hypoxia in untreated 
murine SMA-497 or SMA-560 gliomas were assessed by immunofluorescent stainings for 
CA IX (green) and CD31 (red), using nuclear counterstaining with DAPI (blue). Merged 
images are provided as indicated in right images of each row. G, pSMAD2 levels were 
determined in tumor cells and leukocytes upon B20 treatment in the SMA-560 model in vivo. 
Immunofluorescent stainings were performed for pSMAD2 (green) and CD45 (red), again 
using DAPI as a counterstain. Merged images are provided as indicated in right images of 
each row. Size bars correspond to 100 µM (A,C,D) and 50 µM (B,E-G). Each experimental 
and control group contained 3 mice for histological examination. Each experiment was 
performed at least twice. H,I Gene cluster analysis. Functional interactions between genes up-
regulated in the angiogenic profiles of SMA-497 (H) and GL-261 (I, top) or down-regulated 
in GL-261 (I, bottom) were analyzed in Affymetrix micro-array based gene expression 
profiling by STRING analysis. Interactions with high confidence score of 0.700 were 
integrated to the interactome. Clusters were determined by MCL algorithm and presented with 
different node colors. Inter-cluster edges are represented by dashed-lines 
 
Supplementary Fig. S4 Differential effects of LY2157299 on the growth of murine gliomas. 
Mice intracranially implanted with SMA-497, SMA-540, SMA-560 or GL-261 cells were 
treated daily with LY2157299 at 150 mg/kg or control solvent from day 7 on. A-C Brain 
sections from animals sacrificed when the first mice became symptomatic. A H&E. B 
Immunohistochemical stainings of pSMAD2 (top) and protein levels determined by 
immunoblot (bottom). Values of densitometric analysis of pSMAD2 protein levels, relative to 
β-actin, are shown below the immunoblot panels. (C) CD31. Size bars within images 
correspond to 50 µm (B) and 100 µm (A,C). Each experimental and control group contained 3 
mice for histological examination. Each experiment was performed at least twice. D,E Gene 
cluster analysis. Functional interactions between genes up-regulated in immune response 
pathways in SMA-497 (D) and GL-261 (E,top) or down-regulated in GL-261 (E,bottom/) 
were analyzed by Affymetrix micro-array based gene expression profiling using STRING 
analysis. Interactions with high confidence score of 0.700 were integrated to the interactome. 
Clusters were determined by MCL algorithm and presented with different node colors. Inter-
cluster edges are represented by dashed-lines 
 
Supplementary Fig. S5  Modulation of the VEGF and TGF-β signaling pathway by VEGF in 
vitro. A,B Modulation of TGF-β1 (A) or TGF-β2 (B) mRNA (left) expression was determined 
by RT-PCR 24 h after exposure to VEGF (400 ng/ml), cediranib (100 nM) or B20 (100 
µg/ml). Protein levels (right) were detected in corresponding supernatants by ELISA. Data are 
expressed as mean and SD (n=3) (one-way ANOVA followed by Tukey’s post hoc test, 
confidence interval 99%). C, pSMAD2 levels were assessed by immunoblot. Values of 
densitometric analysis of pSMAD2 protein levels relative to β-actin are shown below the 
immunoblot panels. D,E The cells were treated with TGF-β2 (2 ng/ml) or LY2157299 (1 µM) 
or both for 24 h. VEGF mRNA expression was assessed by RT-PCR (D). In parallel, VEGF 
protein levels were determined by ELISA (E). F,G VEGFR1/2 mRNA (left) and protein 
(right) levels were assessed by immunoblot. mRNA and ELISA data are expressed as mean 
and SD (n=3) (***p<0.001, one-way ANOVA followed by Tukey’s post hoc test confidence 
interval 99%, treated versus SFM, ++p<0.01, +++p<0.001, LY2157299 + TGF-β2 versus 
TGF-β2, ##p<0.01, ###p<0.001, hypoxia versus SFM). Values of densitometric analysis of 
VEGFR protein levels, relative to β-actin, are shown below the immunoblot panels in F and G 
 
Supplementary Fig. S6 Effect of combined B20 and LY2157299 treatment in SMA-497 and 
GL-261 syngeneic models in vivo. Syngeneic mice intracranially implanted with SMA-497 or 
GL-261 cells were treated twice weekly with 5 mg/kg B20 or daily with 150 mg/kg 
LY2157299 or corresponding solvents or both. A-L Brain sections from animals sacrificed 
when the first mice became symptomatic (early-stage) (A-D) and at the time point when each 
specific mouse developed neurological symptoms (end-stage) (E-L) were examined. 
Morphology was assessed by H&E staining (A,E). Brains were immunohistochemically 
stained for CD31 (B,F), pSMAD2 (C,G), CA IX (D,H). I-L Staining of tumor sections to 
visualize vessel normalization was performed with DAPI (I, blue), CD31 (J, red) and ZO-1 
(K, green). Merged images are shown in (L). Size bars correspond to 100 µm (A,B,D-F,H), 50 
µm (C,G) or 10 µm (I,L). Each experimental and control group contained 3 mice for 
histological examination. Each experiment was performed at least twice 
 
Supplementary Fig. S7 Effect of combined B20 and LY2157299 treatment in SMA-497 and 
GL-261 syngeneic models in vivo. Syngeneic mice intracranially implanted with SMA-497 or 
GL-261 cells were treated twice weekly with 5 mg/kg B20 or daily with 150 mg/kg 
LY2157299 or corresponding solvents or both. A-H Brain sections from animals sacrificed 
when the first mice became symptomatic (early-stage) (A-D) and at the time point when each 
specific mouse developed neurological symptoms (end-stage) (E-H) were examined. Brains 
were immunohistochemically stained for CD45 (A,E), CD4 (B,F), CD8 (C,G) or CD11b 
(D,H). Size bars correspond to 50 µm. Each experimental and control group contained 3 mice 
for histological examination. Each experiment was performed at least twice. 
 
Supplementary Fig. S8 pSMAD2 levels in bevacizumab-treated patients. pSMAD2 levels 
were assessed by immunofluorescence microscopy in primary and recurrent tumor tissue of 
patients treated with non-bevacizumab regimens (A) or bevacizumab-containing regimens 
(B). Size bars correspond to 20 µM. Quantification of fluorescent images of the two cohorts 
are provided in C and D. E,F Vessel density scores. Data are expressed as mean and SEM 
(*p<0.05, paired student t-test, primary versus recurrent). 
 
